Your browser doesn't support javascript.
loading
A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis.
Yu, Chen; Zhang, Furen; Ding, Yangfeng; Li, Yumei; Zhao, Yi; Gu, Jun; Guo, Shuping; Pan, Weili; Jin, Hongzhong; Sun, Qing; Kang, Xiaojing; Yang, Qinping; Jiang, Xian; Song, Zhiqiang; Lu, Qianjin; Pang, Xiaowen; Kuang, Yehong; Deng, Danqi; Li, Yuzhen; Zhang, Chunlei; Tao, Juan; Xie, Liangzhi; Wang, Yan; Wang, Jieying; Wang, Gang.
Afiliação
  • Yu C; Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Zhang F; Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China.
  • Ding Y; Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
  • Li Y; Department of Dermatology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
  • Zhao Y; Department of Dermatology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
  • Gu J; Department of Dermatology, Changhai Hospital, Second Military Medical University, Shanghai, China.
  • Guo S; Department of Dermatology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
  • Pan W; Department of Dermatology, Zhejiang provincial People's Hospital, Hangzhou, Zhejiang, China.
  • Jin H; Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Sun Q; Department of Dermatology, Qilu Hospital of Shandong University, Jinan, Shangdong, China.
  • Kang X; Department of Dermatology and Venereology, People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Research Center for Dermatologic Diseases, Xinjiang Key Laboratory of Dermatology Research, Urumqi, Xinjiang, China.
  • Yang Q; Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
  • Jiang X; Department of Dermatology and Venereology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Song Z; Department of Dermatology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
  • Lu Q; Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Pang X; Department of Dermatology, Air Force Medical Center, Chinese People's Liberation Army, Beijing, China.
  • Kuang Y; Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Deng D; Department of Dermatology, the Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
  • Li Y; Department of Dermatology, Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  • Zhang C; Department of Dermatology, Peking Union Medical College Hospital, Beijing, China.
  • Tao J; Department of Dermatology, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Xie L; Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., No.31 Kechuang 7th Street, BDA, Beijing, China; Beijing Protein and Antibody R&D Engineering Center, Sinocelltech Ltd., No.31 Kechuang 7th Street, Beijing, China.
  • Wang Y; Beijing Protein and Antibody R&D Engineering Center, Sinocelltech Ltd., No.31 Kechuang 7th Street, Beijing, China.
  • Wang J; Beijing Protein and Antibody R&D Engineering Center, Sinocelltech Ltd., No.31 Kechuang 7th Street, Beijing, China.
  • Wang G; Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. Electronic address: xjwgang@fmmu.edu.cn.
Int Immunopharmacol ; 112: 109248, 2022 Nov.
Article em En | MEDLINE | ID: mdl-36126411
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Medicamentos Biossimilares Tipo de estudo: Clinical_trials Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Int Immunopharmacol Assunto da revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Medicamentos Biossimilares Tipo de estudo: Clinical_trials Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Int Immunopharmacol Assunto da revista: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China